Okada S, Ishii H, Nose H, Okusaka T, Kyogoku A, Yoshimori M, Wakabayashi K
Department of Internal Medicine, National Cancer Centre Hospital, Chuo-ku, Tokyo, Japan.
Carcinogenesis. 1997 Feb;18(2):445-9. doi: 10.1093/carcin/18.2.445.
The measurement of somatic cell mutation may assist in the assessment of human cancer risk. The glycophorin A (GPA) assay, which measures the frequency of variant erythrocytes in persons with blood type MN, was used to directly assess in vivo mutability in 30 patients with hepatocellular carcinoma (HCC). HCC patients showed significantly increased frequencies of both hemizygous (MO) and homozygous (MM) variants, due to somatic loss of expression of the N allele, when compared with 27 patients with chronic liver disease and 21 healthy controls. The mean elevations of the MO and MM variant frequencies (VF) in HCC patients were 2-3-fold greater than the comparable VF in the control groups. The mean MO and MM VF in the patients with chronic liver disease was slightly elevated compared to that in healthy controls, but the difference was not significant. In the 19 anti-hepatitis C virus (HCV)-positive patients with a history of blood transfusion, significant linear relations between VF and the duration of HCV infection were observed for MO and MM. These data indicate a high background frequency of somatic mutations in HCC patients. The GPA assay may prove to be a useful estimation of the individual's risk of development of HCC.
体细胞突变的测量可能有助于评估人类患癌风险。血型为MN的个体中，用于测量变异红细胞频率的血型糖蛋白A（GPA）检测，被用于直接评估30例肝细胞癌（HCC）患者的体内突变率。与27例慢性肝病患者和21例健康对照相比，HCC患者由于N等位基因的体细胞表达缺失，半合子（MO）和纯合子（MM）变异的频率均显著增加。HCC患者中MO和MM变异频率（VF）的平均升高幅度比对照组中的可比VF高2至3倍。与健康对照相比，慢性肝病患者的平均MO和MM VF略有升高，但差异不显著。在19例有输血史的抗丙型肝炎病毒（HCV）阳性患者中，观察到MO和MM的VF与HCV感染持续时间之间存在显著的线性关系。这些数据表明HCC患者体细胞突变的背景频率很高。GPA检测可能被证明是评估个体患HCC风险的有用方法。
